signed informed consent. Results showed that the maximal platelet aggregation (Agg max ) and 5 min aggregation (Agg late ) with 5-µmol/L ADP in three different CYP2C19 * 2 genotypes were significantly decreased after any drug therapy compared with corresponding baseline measurements (all values P < .05). But percent inhibitions of Agg max and Agg late (IPAs) in CYP2C19 * 2/ * 2 genotype at 4 hours, 24 hours, 3 days, and 7 days after clopidogrel administration were all the lowest among three CYP2C19
Introduction
The recent US Food and Drug Administration (FDA) "boxed warning" on clopidogrel is based on the concern that the antiplatelet effect of clopidogrel depends primarily on its activation by the cytochrome P450 (CYP) system [1] . Patients with decreased CYP2C19 function because of genetic polymorphisms metabolize clopidogrel poorly and have higher rates of cardiovascular events after acute coronary syndrome (ACS) and percutaneous coronary interventions (PCIs) than patients with normal CYP2C19 function [2, 3] . CYP2C19 * 2 is the most common genetic variant reproducibly associated with variability in clopidogrel active metabolite bioavailability, antiplatelet effects, and clinical outcomes [4, 5] . To overcome deficits in clopidogrel responsiveness, one approach is to increase the dose of clopidogrel [6, 7] . Other strategy is to add a third drug (such as Cilostazol) to aspirin and clopidogrel to further enhance platelet inhibition [8] . The other approach is to substitute a newer, more potent platelet inhibitor drug (such as prasugrel) for clopidogrel [9] . However, these strategies that enhanced response to clopidogrel are often associated with a higher risk for bleeding that may be attributed to the overmuch inhibition of the TXA2 and ADP platelet activation pathways that are essential for normal hemostasis [10, 11] . These considerations underscore the need for agents that provide more comprehensive platelet inhibition without interfering with hemostasis, for greater protection against thrombotic events with no incremental bleeding risk. In traditional Chinese medicine (TCM), it is expressed by 2 Evidence-Based Complementary and Alternative Medicine regulating the yin and yang balance [12] , by applying holistic approaches to enhance the system's harmony, a method called dual regulation.
Qi deficiency and blood stasis syndrome is the most common syndrome in patients with coronary heart disease, especially after PCI [13, 14] . Buyang Huanwu decoction (BYHWD), a TCM formula, has been recognized as a treatment for coronary heart diseases with Qi deficiency and blood stasis syndrome and cerebrovascular diseases in clinic [15] . Buchang Naoxintong Jiaonang (BNJ) consists of BYHWD plus Scorpio and Hirudo. Therefore, it was a compound preparation of BYHWD. BNJ is an approved TCM for stroke [16] , which is widely used, and is well tolerated. BNJ combined with aspirin could enhance the antiplatelet effect in patients with cardio-cerebrovascular diseases [17] .
The purpose of this study was to determine the impact of adjunctive BNJ in volunteers with the CYP2C19 * 2 gene mutation accompanied with qi deficiency and blood stasis constitution during treatment of clopidogrel.
Methods

Subject Population.
Male volunteers were eligible for enrollment if they were between 25 and 55 years of age, undergoing medical examination in Fujian Provincial Hospital, and identified as having genotype CYP2C19 * 2. Based on the theory of constitution of TCM [18, 19] , qi deficiency constitution and blood stasis (or stagnant blood) constitution were evaluated. Qi deficiency constitution means insufficiency of primordial QI; lassitude, short breath, and spontaneous perspiration are its main characteristics. Blood stasis constitution means an impeded blood flow; dark or purplish tongue and complexion are its main characteristics. Major exclusion criteria included active bleeding and bleeding diatheses, any antiplatelet or anticoagulation therapy, contraindication to antiplatelet therapy, leukocyte count <3.0 × 10 9 /L, platelet count 100.0 < × 10 9 /L, aspartate aminotransferase or alanine aminotransferase levels >3 times upper normal, serum creatinine level >2.5 mg/dL, having no histories such as cardiovascular or cerebral vessels diseases, diabetes, phlebothrombosis, arterial thrombus, gastritis, peptic ulcer, hepatitis, cholecystitis, renal disease, neoplastic disease, external injury or operation within 6 months, inability to follow the protocol. The Institutional Review Board of Provincial Clinical College of Fujian Medical University approved the study protocol, and the patients provided written informed consent for participation. The study was performed in the Clinical Pharmacological Base of Fujian Provincial Hospital. CYP2C19 * 2 genotyping, adenosine diphosphate-(ADP-) induced platelet aggregation, enzyme immunoassays, and flow cytometry were finished in Fujian Provincial Key Laboratory of cardiovascular disease and Fujian Provincial Clinical Laboratory, respectively. Figure 1 . Eighteen male volunteers with qi deficiency and blood stasis constitution were selected, who were 6 CYP2C19 * 1/ * 1, 6 CYP2C19 * 1/ * 2, and 6 CYP2C19 * 2/ * 2, and signed informed consent. All subjects have stopped taking any medicine two weeks before the study. There were no cigarette smoking, no drinking alcohol, and no drinking coffee during the study. Each subject took clopidogrel 300 mg on the first day and then 75 mg once daily for consecutive six days. After seven washing days, BNJ (0.8 g thrice per day) was taken for five days. Then BNJ-combined clopidogrel were taken for 7 days (the dose was the same as above). BNJ (Naoxintong) 0. 4 
Genotyping by TaqMan Polymerase Chain Reaction (PCR
Genotype CYP2C19 * 2 was performed in medical examination male volunteers (n = 360)
Clopidogrel 300 mg on the first day and then 75 mg once daily for consecutive six days after signing informed consent after washing, 5 days after BNJ administration, and 7 days after BNJ combined clopidogrel, and measure the platelet count, platelet functional (ADP-induced platelet aggregation, Platelet activation of the membrane marker P-selectin (CD62p), and Platelet Activator combined-l (PAC-1) with flow cytometry) and inflammatory index (Soluble CD40L (sCD40L) with enzyme-linked Immunosorbent assay) at baseline, 7 days after clopidogrel administration, 5 days after BNJ administration, and 7 days after BNJ-combined clopidogrel, respectively. Hemoglobin (Hb), Platelet count, fasting plasma glucose (FSG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), plasma total cholesterol (TC), and plasma creatinine (Cr) were remeasured at baseline and the end of the test, respectively. Creatinine clearance rate (CGCCr) was calculated by Cockcroft/Gault formula: CGCCr = (140-age) * (Wt in kg) * (0.85 if female)/ (72 * Cr).
Adenosine Diphosphate-Induced Platelet Aggregation.
Aggregation studies were performed within 2 hours after blood collection, at 37
• C, by using a turbidimetric method of Born [20] on an LBY-NJ4-channel platelet aggregation analyzer (Beijing Precil Instrument Co., Ltd). The whole blood was centrifuged at 700 rpm for 4 min to prepare platelet-rich plasma (PRP). The remaining blood was further centrifuged at 3500 rpm for 10 min to prepare platelet-poor plasma (PPP (Tables 2 and 3 ). All subjects completed the treatment allocated in the study protocol. All treatments were well tolerated, and no subject discontinued the study drugs. Compared with baseline, Hb, platelet count, blood biochemical indicators at the end of the test had no significant difference in three different CYP2C19 * 2 genotypes, except for CGCCr in CYP2C19 * 1/ * 1 genotype (Tables 3 and 4) . Baseline percentages of platelet disaggregation with 5-µmol/L ADP stimuli had no significant difference among three different CYP2C19 * 2 genotypes. After clopidogrel therapy, percentages of platelet disaggregation were significantly different in three different CYP2C19 * 2 genotypes (Figure 4) Note: values are presented as mean ± SD. The P values are for comparison to baseline.
ADP-Induced Platelet
7 days after washing, percentages of platelet disaggregation in CYP2C191/ * 2 genotype was higher than those in CYP2C19 * 1/ * 1 genotype (P < .05). Percentages of platelet disaggregation 5 days after BNJ administration or 7 days after BNJ-combined clopidogrel had no significant difference among three different CYP2C19 * 2 genotypes (Figure 4 ).
Platelet Count, Platelet Activation, and Inflammation.
There were no significant differences in platelet count after treatment compared with corresponding baseline measurements, except for subjects in CYP2C19 * 2/ * 2 genotype (Table 3) . Changes of platelet count were not significantly different among three CYP2C19 * 2 genotypes ( Figure 5 ). CD62P, PAC1, and sCD40L were significantly reduced after clopidogrel administration or adjunctive BNJ-compared with corresponding baseline measurements (P < .01). After BNJ or BNJ combined clopidogrel, changes of these parameters were similar to changes of ADP-induced platelet aggregation in three different CYP2C19 * 2 genotypes ( Figure 5 ).
Discussion
This ABNJC-CYP2C19 * 2 study is the first to demonstrate that adjunctive BNJ to clopidogrel can intensify platelet inhibition in volunteers with the CYP2C19 * 2 gene mutation including heterozygous (CYP2C19 * 1/ * 2) and homozygous for mutations (CYP2C19 * 2/ * 2). Furthermore, this study showed that adjunctive BNJ as compared with clopidogrel of 75 mg/day resulted in less platelet aggregation in CYP2C19 * 2 gene mutation. These results provide a rationale for further studies to assess whether adjunctive BNJ, as compared with other intensified regimens, provides long-term clinical benefits in patients with CYP2C19 * 2 gene mutation. CYP2C19 plays an important role in the bioactivation of clopidogrel. The CYP2C19 * 2 allele is one of the mutations responsible for the phenotype known as poor clopidogrel metabolizer. The genetic polymorphism has been associated with a poor response to clopidogrel in healthy volunteers [21] . The clinical efficacy data mirror the effect of genetic polymorphisms on platelet function in both heterozygotes as well as homozygotes. Carriers of a CYP2C19 * 2 allele have been found to have an absolute reduction in platelet aggregation in response to clopidogrel that was 9 percentage points less than that of noncarriers [22] . In addition, medications metabolized by CYP450, such as omeprazole (an inhibitor of CYP2C19), have been shown to influence clopidogrel effect. Omeprazole has been associated with a lower efficacy of clopidogrel as assessed by the platelet reactivity index vasoactive-stimulated phosphoprotein [23] .
TCM is an essential part of the health care system in several Asian countries and is considered a complementary or alternative medical system in most Western countries. Researchers are going to pay close attention to the regulation of Chinese materia medica on cytochrome P450 system [24] . Chan et al. [25] suggest that the interactions between Clopidogrel and Angelica dahurica or Ginkgo biloba or Scutellaria baicalensis can inhibit activities of CYP2C9 enzymes.
The ingredients of BNJ include Radix Astragali, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, Semen Persicae, Flos Carthami, Resina Olibani, Myrrha, Caulis Spatholobi, Radix Achyranthis Bidentatae, Ramulus Cinnamomi, Ramulus Mori, Pheretima, Scorpio, and Hirudo. Wang's studies observed that Astragalus saponins are the essential component of BNJ confirmed by HPLC-MS [26] . The regulation of Astragalus saponins on cytochrome P450 system has not been reported. Xia's studies showed that Angelica sinensis Polysaccharides can modulate the activities of Evidence-Based Complementary and Alternative Medicine 9 drug metabolism enzymes [27] . In our study, we observe that adjunctive BNJ can overcome an attenuation of the antiplatelet effect of clopidogrel in volunteers with the CYP2C19 * 2 gene mutation accompanied with qi deficiency and blood stasis constitution as demonstrated by all aggregometric and flow cytometric parameters obtained. Further researches should be undertaken to determine which ingredient or constituents of BNJ are with potential of CPY2C19 modulation.
Study Limitations.
Although prospective, our study population is small, and they are not patients. Due to the difficulties in identifying the active constituents responsible for the modulation of CPY2C19 enzyme, prediction of BNJclopidogrel metabolic interactions is difficult.
Conclusions
Among volunteers with the CYP2C19 * 2 gene mutation accompanied with qi deficiency and blood stasis constitution, adjunctive BNJ achieves intensified platelet inhibition as compared with clopidogrel of 75 mg/day. It needs to be evaluated whether the therapy could be translated into improved clinical outcomes.
